Editor's Note Preliminary research shows removing breasts or ovaries can significantly improve survival and reduce recurrence risk in young breast cancer patients with BRCA mutations, HealthDay reported December 13. The findings were presented this week at the San Antonio Breast Cancer Symposium. According to the article, researchers analyzed data from…

Read More

Editor's Note Active monitoring for certain breast cancer patients offers similar outcomes to surgery with fewer side effects, according to research detailed in a December 16 article from Oncology News Central. Presented at the 2024 San Antonio Breast Cancer Symposium and published in JAMA, The COMET trial supports the safety…

Read More

Editor's Note Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative early breast cancer provides noninferior outcomes compared to undergoing the procedure, MedPage Today reported December 13. Presented at the San Antonio Breast Cancer Symposium and published in the New England Journal of Medicine, the INSEMA trial found…

Read More

Editor's Note Perioperative immunotherapy is reshaping treatment strategies for early-stage non-small cell lung cancer (NSCLC) without actionable mutations, according to Dr. Roy S. Herbst of Yale Cancer Center. In a recent interview with OncLive, the oncology expert highlighted the promise of neoadjuvant and adjuvant therapies to improve outcomes for these…

Read More

Editor's Note An algorithm developed by researchers at Duke University Medical Centre is designed to assist patients diagnosed with intermediate-stage liver cancer in making decisions about surgery, according to an October 9 report in News Medical Life Sciences. Known as the Modified Metroticket, this tool predicts overall survival and recurrence-free…

Read More

Editor's Note The US Food & Drug Administration (FDA) has approved immunotherapy durvalumab for perioperative treatment of resectable non-small cell lung cancer (NSCLC), according to an August 15 announcement. The approval is for durvalumab (Imfinzi, AstraZeneca) in combination with platinum-based chemotherapy as a neoadjuvant treatment, followed by durvalumab alone as…

Read More

Editor's Note A post hoc analysis of the SCOT phase 3 randomized clinical trial reveals that initiating adjuvant chemotherapy more than 6 weeks after surgery is linked to worse disease-free survival (DFS) in patients with high-risk stage II and stage III colorectal cancer. Published June 12 in JAMA Surgery, the…

Read More

Editor's Note Medical professionals have long accepted that bilateral mastectomy does not improve survival outcomes for breast cancer patients. However, a study published in JAMA Oncology reveals a puzzling finding: Those who develop a second cancer in the other breast have a higher risk of death. As detailed in a…

Read More

Editor's Note Early-onset colorectal cancer (EO-CRC), diagnosed before age 50, is increasing in incidence worldwide. Despite existing postoperative colonoscopy surveillance strategies, the optimal intervals for EO-CRC patients are unclear due to limited long-term data. This study, titled “Early-onset Colorectal Cancer Patients Do Not Require Shorter Intervals for Post-surgical Surveillance Colonoscopy”…

Read More

Editor's Note In a recent study, an artificial intelligence (AI) system detected more clinically significant prostate cancers and fewer indolent cancers than human radiologists reading MRIs, MedPage today reported June 13. The MedPage report covers a study published in Lancet Oncology that, according to researchers, “provided evidence that AI systems,…

Read More